相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Quetelet (body mass) index and effects of dapagliflozin in chronic kidney disease
Glenn M. Chertow et al.
DIABETES OBESITY & METABOLISM (2022)
SGLT inhibitors on weight and body mass: A meta-analysis of 116 randomized-controlled trials
Alex Jia Yang Cheong et al.
OBESITY (2022)
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial
Kazuma Oyama et al.
EUROPEAN HEART JOURNAL (2022)
Dapagliflozin for heart failure according to body mass index: the DELIVER trial
Carly Adamson et al.
EUROPEAN HEART JOURNAL (2022)
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program
Brendon L. Neuen et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease Insights From the CREDENCE Trial
Nan Ye et al.
CIRCULATION (2021)
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia
Qiuhe Ji et al.
DIABETES OBESITY & METABOLISM (2021)
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
Toshiaki Ohkuma et al.
DIABETES OBESITY & METABOLISM (2020)
Impact of gastrointestinal physiology on drug absorption in special populations – An UNGAP review
Cordula Stillhart et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program
Brendon L. Neuen et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters
Cornelis Smit et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
Lennart Tonneijck et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Meg J. Jardine et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial
Bruce Neal et al.
DIABETES OBESITY & METABOLISM (2017)
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus
Muhammad A. Abdul-Ghani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial
Bruce Neal et al.
AMERICAN HEART JOURNAL (2013)
The magnitude of association between overweight and obesity and the risk of diabetes: A meta-analysis of prospective cohort studies
Asnawi Abdullah et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults
Katherine M. Flegal et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2009)